Related Experiment Videos
Antitumor chemosensitivity differs between clinical sarcoma and adenocarcinoma tissues
H Takeuchi1, H Baba, S Inutsuka
1Cancer Center of Kyushu University Hospital, Fukuoka, Japan.
Anticancer Research
|January 1, 1994
Summary
Osteosarcoma tissues showed higher chemosensitivity to several antitumor drugs compared to stomach adenocarcinoma. Liposarcoma and leiomyosarcoma chemosensitivity varied, suggesting tailored treatment approaches.
Area of Science:
- Oncology
- Pharmacology
- Biochemistry
Background:
- Chemosensitivity testing is crucial for optimizing cancer treatment.
- Human sarcoma subtypes (osteosarcoma, leiomyosarcoma, liposarcoma) and gastric adenocarcinoma have distinct cellular characteristics.
Purpose of the Study:
- To compare the in vitro chemosensitivity of human sarcoma tissues with gastric adenocarcinoma.
- To evaluate the efficacy of specific antitumor drugs across different cancer types.
Main Methods:
- The succinate dehydrogenase inhibition (SDI) test was employed to assess chemosensitivity.
- Human sarcoma (n=43) and gastric adenocarcinoma (n=28) tissues were exposed to adriamycin, 5-fluorouracil, mitomycin C, cisplatin, aclacinomycin A, and carboquone for 3 days.
- Cell viability was quantified using the MTT assay to measure succinate dehydrogenase activity.
Main Results:
- Osteosarcoma exhibited significantly lower succinate dehydrogenase activity compared to adenocarcinoma when treated with adriamycin, mitomycin C, cisplatin, aclacinomycin A, and carboquone.
- Leiomyosarcoma showed higher sensitivity to adriamycin, while liposarcoma demonstrated increased sensitivity to cisplatin and aclacinomycin A.
- Osteosarcoma displayed a higher sensitivity rate to adriamycin, mitomycin C, and cisplatin than adenocarcinoma.
Conclusions:
- Osteosarcoma patients may respond favorably to conventional antitumor drugs.
- For resistant liposarcoma or leiomyosarcoma, surgical resection and combined modalities like radiation and hyperthermia should be considered.